Whitehouse Laboratories Announces Development of Container Testing Center - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Whitehouse Laboratories Announces Development of Container Testing Center



Untitled Document

Whitehouse Laboratories announced the expansion of a new laboratory dedicated to container testing. The expansion will include will a 5000 ft2 laboratory for routine container testing and a Container Closure Integrity Test (CCIT) facility. The laboratory is expected to be complete by February 1, 2014.

The laboratory will contain all instruments required to meet the new USP routine testing directives expected in 2014. In addition, the CCIT laboratory will provide method development, validation, and testing services, which include helium flow, vacuum decay, electrical conductivity, laser diffraction, and residual seal force. The facility will also include onsite capping ability and a full-service package distribution laboratory. The laboratory will be under the direction of Brian Mulhall, who has over 20 years of container and package testing experience.

Source: Whitehouse Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here